Novo Nordisk AS (XBUL:NOV) Debt-to-Asset : 0.14 (As of Sep. 2024)

View and export this data going back to 2021. Start your Free Trial

What is Novo Nordisk AS Debt-to-Asset?

Novo Nordisk AS's Short-Term Debt & Capital Lease Obligation for the quarter that ended in Sep. 2024 was лв1,529 Mil. Novo Nordisk AS's Long-Term Debt & Capital Lease Obligation for the quarter that ended in Sep. 2024 was лв14,256 Mil. Novo Nordisk AS's Long-Term Debt & Capital Lease ObligationTotal Assets for the quarter that ended in Sep. 2024 was лв110,118 Mil. Novo Nordisk AS's debt to asset for the quarter that ended in Sep. 2024 was 0.14.

Novo Nordisk AS Debt-to-Asset Historical Data

The historical data trend for Novo Nordisk AS's Debt-to-Asset can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Novo Nordisk AS Debt-to-Asset Chart

Novo Nordisk AS Annual Data

Trend

Dec14

Dec15

Dec16

Dec17

Dec18

Dec19

Dec20

Dec21

Dec22

Dec23

Debt-to-Asset

Get a 7-Day Free Trial

0.04

0.07

0.14

0.11

0.09

Novo Nordisk AS Quarterly Data
	Dec19	Mar20	Jun20	Sep20	Dec20	Mar21	Jun21	Sep21	Dec21	Mar22	Jun22	Sep22	Dec22	Mar23	Jun23	Sep23	Dec23	Mar24	Jun24	Sep24
Debt-to-Asset	Get a 7-Day Free Trial															0.09	0.09	0.09	0.15	0.14

Competitive Comparison of Novo Nordisk AS's Debt-to-Asset

For the Drug Manufacturers - General subindustry, Novo Nordisk AS's Debt-to-Asset, along with its competitors' market caps and Debt-to-Asset data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Novo Nordisk AS's Debt-to-Asset Distribution in the Drug Manufacturers Industry

For the Drug Manufacturers industry and Healthcare sector, Novo Nordisk AS's Debt-to-Asset distribution charts can be found below:

* The bar in red indicates where Novo Nordisk AS's Debt-to-Asset falls into.

Novo Nordisk AS Debt-to-Asset Calculation

Debt to Asset measures the financial leverage a company has.

Novo Nordisk AS's Debt-to-Asset for the fiscal year that ended in Dec. 2023 is calculated as

Debt-to-Asset	=	Total Debt			/	Total Assets
	=	(Short-Term Debt & Capital Lease Obligation	+	Long-Term Debt & Capital Lease Obligation)	/	Total Assets
	=	(1764.169	+	5590.438)	/	85644.705
	=	0.09

Novo Nordisk AS's Debt-to-Asset for the quarter that ended in Sep. 2024 is calculated as

Debt-to-Asset	=	Total Debt			/	Total Assets
	=	(Short-Term Debt & Capital Lease Obligation	+	Long-Term Debt & Capital Lease Obligation)	/	Total Assets
	=	(1529.411	+	14255.658)	/	110117.838
	=	0.14

Novo Nordisk AS (XBUL:NOV) Debt-to-Asset Explanation

In the calculation of Debt-to-Asset, we use the total of Short-Term Debt & Capital Lease Obligation and Long-Term Debt & Capital Lease Obligation divided by Total Assets.

Novo Nordisk AS Debt-to-Asset Related Terms

Thank you for viewing the detailed overview of Novo Nordisk AS's Debt-to-Asset provided by GuruFocus.com. Please click on the following links to see related term pages.

Novo Nordisk AS Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Drug Manufacturers » Novo Nordisk AS (XBUL:NOV) » Definitions » Debt-to-Asset

Comparable Companies

Traded in Other Exchanges

NONOF:USA NVO:USA NOVOB:Mexico NVO:Mexico 0TDD:UK NOVOBc:UK 0QIU:UK NOVO B:Denmark NOV:Germany NOV:Germany NOVA:Germany NOV:Germany NOV:Germany NOVA:Germany N1VO34:Brazil NNO2:Austria

Address

Novo Alle 1, Bagsvaerd, DNK, 2880

Website

https://www.novonordisk.com

With roughly one third of the global branded diabetes treatment market, Novo Nordisk is the leading provider of diabetes-care products in the world. Based in Denmark, the company manufactures and markets a variety of human and modern insulins, injectable diabetes treatments such as GLP-1 therapy, oral antidiabetic agents, and obesity treatments. Novo also has a biopharmaceutical segment (constituting roughly 10% of revenue) that specializes in protein therapies for hemophilia and other disorders.